Advertisement
UK markets closed

  • NIKKEI 225

    38,490.17
    -347.29 (-0.89%)
     

  • HANG SENG

    18,424.96
    -19.15 (-0.10%)
     

  • CRUDE OIL

    74.19
    +0.94 (+1.28%)
     

  • GOLD FUTURES

    2,374.90
    +27.50 (+1.17%)
     

  • DOW

    38,786.45
    +75.16 (+0.19%)
     

  • Bitcoin GBP

    55,533.50
    +652.66 (+1.19%)
     

  • CMC Crypto 200

    1,511.60
    +37.86 (+2.57%)
     

  • NASDAQ Composite

    17,160.50
    +303.46 (+1.80%)
     

  • UK FTSE All Share

    4,502.58
    +5.70 (+0.13%)
     
Money:

How to choose between saving and investing your money

Does it make sense to compare long term averages of investments with the peak of savings rates?

Sera Prognostics First Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.34 loss in 1Q 2023)

editorial-team@simplywallst.com (Simply Wall St)
·1-min read

Sera Prognostics (NASDAQ:SERA) First Quarter 2024 Results

Key Financial Results

  • Net loss: US$8.10m (loss narrowed by 23% from 1Q 2023).

  • US$0.25 loss per share (improved from US$0.34 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sera Prognostics Earnings Insights

Looking ahead, revenue is forecast to grow 95% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 7.9% from a week ago.

Risk Analysis

Be aware that Sera Prognostics is showing 5 warning signs in our investment analysis and 1 of those doesn't sit too well with us...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.